Paying the price for late starts and early stops: Racial and sex disparities in HIV-related mortality

Clinical Infectious Diseases

Volumn 49, Issue 10, 2009, Pages 1579-1581

  Smith, Kimberly Y ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; HEALTH BEHAVIOR; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; MORTALITY; NOTE; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; SCREENING; SEX DIFFERENCE; SURVIVAL RATE;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; CONTINENTAL POPULATION GROUPS; FEMALE; HIV INFECTIONS; HUMANS; LIFE EXPECTANCY; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RISK-TAKING; SEX FACTORS; SURVIVAL ANALYSIS; UNITED STATES; YOUNG ADULT;

EID: 72849115453     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/644773     Document Type: Note

References (14)

1. Centers for Disease Control and Prevention. HIV/AIDS surveillance report: cases of HIV infection and AIDS in the United States, 2006. HIV/AIDS Surveillance Report, Volume 18. Available at: http://www.cdc.gov/hiv/topics/ surveillance/resources/reports/2006report/default.htm. Accessed 24 Spetember 2009.
2. Centers for Disease Control and Prevention. HIV/AIDS surveillance report: cases of HIV infection and AIDS in the United States, 2007. HIV/AIDS Surveillance Report, Volume 19. Available at: http://www.cdc.gov/hiv/topics/ surveillance/resources/reports/2007report/default.htm. Accessed 24 Spetember 2009.
3. Losina E, Schackman BR, Sadownik SN, et al. Racial and sex disparities in life expectancy losses among HIV-infected persons in the United States: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis 2009; 49: 1570-1578 (in this issue).
4. Centers for Disease Control and Prevention. Late versus early testing of HIV-16 Sites, United States, 2002-2003. MMWR Morb Mortal Wkly Rep 2003; 52:581-586
5. McNaghten A, Hanson DL, Kellerman S, et al. Factors associated with immunologic stage at which patients initiate antiretroviral therapy (abstract 473-M). In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections; 24-28 February 2002 (Seattle, Washington). 2002.
6. Centers for Disease Control and Prevention. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Morb Mortal Wkly Rep 2006; 55(RR14):1-17.
7. Kitahata MM, Gange SG, Abraham AG, et al. Effect of early vs deferred antiretroviral therapy for HIV on survival. New Eng J Med 2009; 360:1315-1326
8. Barron Y, Cole SR, Greenblatt RM, et al. Effect of discontinuing antiretroviral therapy on survival of women initiated on highly active antiretroviral therapy. AIDS 2004; 18:1579-1584 (Pubitemid 39037482) (Pubitemid 39037482)
9. Cunningham WE, Andersen RM, Katz MH, et al. The impact of competing subsistence needs and barriers on access to medical care for persons with human immunodeficiency virus receiving care in the United States. Med Care 1999; 37:1270-1281
10. Anastos K, Schneider, MF, Gange, SJ, et al. The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy inwomen. J Acquir Immune Defic Syndr 2005; 39:537-544 (Pubitemid 41098467)
11. Cohen MH, Cook JA, Grey D, et al. Medically eligible women who do not use HAART: importance of abuse, drug use and race. Am J Public Health 2004; 94:147-151 (Pubitemid 38857315)
12. US Census Bureau. The 2009 statistical abstract. Available at: http://www.census.gov/compendia/statab/cats/births-deaths-marriages-divorces/ life-expectancy.html. Accessed 28 September 2009.
13. Hessol NA, Kalinowski A, Benning L, et al. Mortality among participants in the Multicenter AIDS Cohort Study and the Womeňs Interagency HIV Study. Clin Infect Dis 2007; 44:287-294 (Pubitemid 46079997) (Pubitemid 46079997)
14. Anastos K, Gange SJ, Lau B, et al. Association of race and gender with HIV-1 RNA levels and immunologic progression. J Acquir Immune Defic Syndr 2000; 24:218-226 (Pubitemid 30748925)